Kerem Ozcan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kerem Ozcan has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Olca Basturk
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
37 shared publications - Eileen Mary O'Reilly
Weill Cornell Medicine
25 shared publications - James J. Harding
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
25 shared publications - Marc Ladanyi
Memorial Sloan Kettering Cancer Center 1 Department of Pathology and Laboratory Medicine New York, New York
25 shared publications - Abhinita Mohanty
Center for Computational and Integrative Biology, Rutgers University
24 shared publications - Angela Rose Brannon
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
24 shared publications
Latest Publications
- 19 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
Spatial Transcriptomics on a Diverse Pancreatic Cancer Cohort Reveals Race-Related Differences in Tumor Subtypes and Immune Microenvironments
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy 20% more likely to develop in Black African Americans (BAA) compared to Non-African Americans (NAA). Large-scale gene expression analysis of tumor subtypes and cellular microenvironments in a diverse PDAC cohort could help provide insights into cell and molecular differences in BAA cancer cells. Here, we conducted a multi-omics interrogation of BAA versus NAA PDAC using whole exome sequencing, spatial transcriptomics (ST), and spatial proteomics. Whole exome sequencing confirmed patient ancestry and showed no significant differences in driver mutations between race groups. BAA PDAC tumors had significantly fewer classical molecular subtype cells with no change in more aggressive basal-like cells. Instead, BAA patients showed a significant enrichment of the intermediate/hybrid subtype compared to NAA patients. BAA tumors also displayed increased B cell and reduced myeloid cell interactions compared to NAA tumors. Analysis of tertiary lymphoid structures in a validation cohort revealed that tumors in BAA patients displayed larger TLS size and number compared to NAA. In conclusion, these findings identify an increased intermediate molecular subtype signature in BAA tumors at the expense of cells with a classical subtype, accompanied by a distinct immune cell composition and spatial distribution. This study highlights that health disparities in patients of different ancestries may have a molecular basis that influences tumor aggressiveness and the immune response, which may inform therapeutic strategies.
- 19 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
Spatial Transcriptomics on a Diverse Pancreatic Cancer Cohort Reveals Race-Related Differences in Tumor Subtypes and Immune Microenvironments
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy 20% more likely to develop in Black African Americans (BAA) compared to Non-African Americans (NAA). Large-scale gene expression analysis of tumor subtypes and cellular microenvironments in a diverse PDAC cohort could help provide insights into cell and molecular differences in BAA cancer cells. Here, we conducted a multi-omics interrogation of BAA versus NAA PDAC using whole exome sequencing, spatial transcriptomics (ST), and spatial proteomics. Whole exome sequencing confirmed patient ancestry and showed no significant differences in driver mutations between race groups. BAA PDAC tumors had significantly fewer classical molecular subtype cells with no change in more aggressive basal-like cells. Instead, BAA patients showed a significant enrichment of the intermediate/hybrid subtype compared to NAA patients. BAA tumors also displayed increased B cell and reduced myeloid cell interactions compared to NAA tumors. Analysis of tertiary lymphoid structures in a validation cohort revealed that tumors in BAA patients displayed larger TLS size and number compared to NAA. In conclusion, these findings identify an increased intermediate molecular subtype signature in BAA tumors at the expense of cells with a classical subtype, accompanied by a distinct immune cell composition and spatial distribution. This study highlights that health disparities in patients of different ancestries may have a molecular basis that influences tumor aggressiveness and the immune response, which may inform therapeutic strategies.
- Open Access
- 13 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (5) , 847-855
NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer
Background: NRG1 fusions are unique oncogenic drivers that activate the HER3/HER2/PI3K pathway. The US Food and Drug Administration granted accelerated approval to a HER2/HER3 antibody, zenocutuzumab, for treatment of NRG1 fusion-positive non–small cell lung cancer and pancreatic ductal adenocarcinoma (PDAC). The optimal detection methods and clinicopathological features of patients with NRG1 fusion-positive cancer have not been systematically studied. Here, we review NRG1 fusion-positive cancer and focus on outcomes in PDAC. Methods: Patients with NRG1 fusion-positive disease at Memorial Sloan Kettering Cancer Center were identified using institutional databases. Clinicopathological data were extracted from medical records. NRG1 fusion-positive PDAC cases underwent review of radiology, pathology, treatment data, and assessment of progression-free and overall survival. Results: Of 76 531 patients, 48 NRG1 fusion-positive cases were identified. The most common tumor types were lung (60%), PDAC (21%), and breast (10%). Approximately half (46%) of these patients received HER2- and/or HER3-directed therapy. Patients were identified by RNA (n = 34), DNA (n = 11), or both (n = 3). RNA was superior to DNA for fusion identification. Twenty-one fusion partners were detected, most commonly CD74 (40%) and ATP1B1 (10%). Lung cancers were otherwise driver negative, and PDAC cases were KRAS wild type. NRG1 fusion-positive PDAC exhibited distinct histopathological and clinical features. Median patient age was 48.5 years, median progression-free survival on first-line chemotherapy was 12.6 months (n = 7; 95% confidence interval [CI] = 2.9 to not reached), and median overall survival from diagnosis was 39.6 months (n = 9; 95% CI = 23.2 to not reached). Conclusions: NRG1 fusions are a newly described, clinically actionable target in solid tumors. We report the landscape of NRG1 fusion-positive cancers and highlight the importance of RNA testing. NRG1 fusion-positive PDAC is enriched in younger patients with KRAS wild-type disease and has unique biology.
- 13 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (5) , 847-855
Open AccessNRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer
Background: NRG1 fusions are unique oncogenic drivers that activate the HER3/HER2/PI3K pathway. The US Food and Drug Administration granted accelerated approval to a HER2/HER3 antibody, zenocutuzumab, for treatment of NRG1 fusion-positive non–small cell lung cancer and pancreatic ductal adenocarcinoma (PDAC). The optimal detection methods and clinicopathological features of patients with NRG1 fusion-positive cancer have not been systematically studied. Here, we review NRG1 fusion-positive cancer and focus on outcomes in PDAC. Methods: Patients with NRG1 fusion-positive disease at Memorial Sloan Kettering Cancer Center were identified using institutional databases. Clinicopathological data were extracted from medical records. NRG1 fusion-positive PDAC cases underwent review of radiology, pathology, treatment data, and assessment of progression-free and overall survival. Results: Of 76 531 patients, 48 NRG1 fusion-positive cases were identified. The most common tumor types were lung (60%), PDAC (21%), and breast (10%). Approximately half (46%) of these patients received HER2- and/or HER3-directed therapy. Patients were identified by RNA (n = 34), DNA (n = 11), or both (n = 3). RNA was superior to DNA for fusion identification. Twenty-one fusion partners were detected, most commonly CD74 (40%) and ATP1B1 (10%). Lung cancers were otherwise driver negative, and PDAC cases were KRAS wild type. NRG1 fusion-positive PDAC exhibited distinct histopathological and clinical features. Median patient age was 48.5 years, median progression-free survival on first-line chemotherapy was 12.6 months (n = 7; 95% confidence interval [CI] = 2.9 to not reached), and median overall survival from diagnosis was 39.6 months (n = 9; 95% CI = 23.2 to not reached). Conclusions: NRG1 fusions are a newly described, clinically actionable target in solid tumors. We report the landscape of NRG1 fusion-positive cancers and highlight the importance of RNA testing. NRG1 fusion-positive PDAC is enriched in younger patients with KRAS wild-type disease and has unique biology.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
Mitochondrial profiling reveals context-specific features of breast cancer cells in primary tumors and metastases
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
Mitochondrial profiling reveals context-specific features of breast cancer cells in primary tumors and metastases
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
SLC25A39-mediated mitochondrial GSH import is essential for metastasis but dispensable for primary tumor growth
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
SLC25A39-mediated mitochondrial GSH import is essential for metastasis but dispensable for primary tumor growth
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
Antioxidant supplementation fails to rescue metastatic defects caused by SLC25A39 loss
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
Antioxidant supplementation fails to rescue metastatic defects caused by SLC25A39 loss
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
In vivo CRISPR screening of breast cancer cell lines during metastasis
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
In vivo CRISPR screening of breast cancer cell lines during metastasis
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
ATF4 overexpression bypasses the requirement for mitochondrial GSH during metastasis
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
ATF4 overexpression bypasses the requirement for mitochondrial GSH during metastasis
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
Primers and DNA oligos used in this study
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
Primers and DNA oligos used in this study
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
Antibodies and reagents used in study
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
Antibodies and reagents used in study
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
Cancer cells require substantial metabolic adaptations to metastasize to distant organs, but the metabolites essential for successful colonization remain poorly defined. In this study, we used a mitochondrial metabolomics approach to compare primary and metastatic breast cancer cells. This analysis revealed accumulation of mitochondrial glutathione (GSH) during lung metastasis, driven by elevated expression of SLC25A39, a mitochondrial GSH transporter. Loss of SLC25A39 impairs metastatic colonization in genetic screens, cell line models, and patient-derived xenografts, without affecting primary tumor growth. Mitochondrial GSH import is specifically required during early colonization and functions independently of its canonical antioxidant role. CRISPR activation screens identified ATF4, a stress-induced transcription factor, as a bypass mechanism that restores metastatic potential in SLC25A39-deficient cells. Mechanistically, SLC25A39 is required for optimal ATF4 activation during metastasis and under hypoxia, linking mitochondrial GSH availability to integrated stress response signaling. These findings identify mitochondrial GSH as a necessary and limiting metabolite for metastatic progression.Significance:Mitochondrial GSH import via SLC25A39 is essential for early metastatic colonization in breast cancer, linking metabolic adaptation to stress response signaling. Targeting this pathway may uncover a therapeutic vulnerability specific to metastasis without affecting primary tumor growth.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling
Cancer cells require substantial metabolic adaptations to metastasize to distant organs, but the metabolites essential for successful colonization remain poorly defined. In this study, we used a mitochondrial metabolomics approach to compare primary and metastatic breast cancer cells. This analysis revealed accumulation of mitochondrial glutathione (GSH) during lung metastasis, driven by elevated expression of SLC25A39, a mitochondrial GSH transporter. Loss of SLC25A39 impairs metastatic colonization in genetic screens, cell line models, and patient-derived xenografts, without affecting primary tumor growth. Mitochondrial GSH import is specifically required during early colonization and functions independently of its canonical antioxidant role. CRISPR activation screens identified ATF4, a stress-induced transcription factor, as a bypass mechanism that restores metastatic potential in SLC25A39-deficient cells. Mechanistically, SLC25A39 is required for optimal ATF4 activation during metastasis and under hypoxia, linking mitochondrial GSH availability to integrated stress response signaling. These findings identify mitochondrial GSH as a necessary and limiting metabolite for metastatic progression.Significance:Mitochondrial GSH import via SLC25A39 is essential for early metastatic colonization in breast cancer, linking metabolic adaptation to stress response signaling. Targeting this pathway may uncover a therapeutic vulnerability specific to metastasis without affecting primary tumor growth.